Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)

BACKGROUND: The appropriate number of chemotherapy cycles for limited stage diffuse large B-cell lymphoma (DLBCL) patients without gross residual lesions after complete resection, has not been specifically questioned. We performed a multicenter, single-arm, phase 2 study to investigate the feasibili...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Dok Hyun, Sohn, Byeong Seok, Oh, Sung Yong, Lee, Won-Sik, Lee, Sang Min, Yang, Deok-Hwan, Huh, Jooryung, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355104/
https://www.ncbi.nlm.nih.gov/pubmed/28076329
http://dx.doi.org/10.18632/oncotarget.14531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355104/
https://www.ncbi.nlm.nih.gov/pubmed/28076329
http://dx.doi.org/10.18632/oncotarget.14531

Ejemplares similares